Phenotypic Heterogeneity in Two Unrelated Danon Patients Associated with the Same LAMP‐2 Gene Mutation

Abstract

Danon disease, an X-linked cardioskeletal myopathy caused by primary deficiency of lysosome-associated membrane protein-2 (LAMP-2), is clinically characterized by cardiomyopathy, myopathy, and variable mental retardation. The pathological hallmark of the disease is the absence of LAMP-2 immunohistochemical staining in muscle. The LAMP-2 gene mutations reported thus far are generally private mutations. We describe two cases of Danon disease with different clinical presentation, in whom we identified the same exon skipping mutation c.928G>A in the LAMP-2 gene. The first patient was affected by an early onset myopathy and hypertrophic cardiomyopathy (HCM) that partially improved with drug treatment. A first muscle biopsy at age 4 months showed markedly increased glycogen, and acid maltase deficiency was ruled out biochemically. A second muscle biopsy, performed at age 3œ years, showed very mild abnormalities. The second child at age 15 years had mild, diffuse muscle weakness and wasting, moderate mental deficiency, and HCM. Two serial biopsies performed at age 8 and 15 years showed similar findings of multiple esterase-positive vacuoles in type I myofibers. In both patients the immunohistochemical study demonstrated the absence of LAMP-2 in skeletal muscle.

Key words

Danon disease - hypertrophic cardiomyopathy - LAMP‐2

References

• 1 Arad M, Maron B J, Gorham J M, Johnson Jr W H, Saul J P, Perez-Atayde. et al . Glycogen storage diseases presenting as hypertrophic cardiomyopathy.  N Engl J Med. 2005;  352 362-372
• 2 Horvath J, Ketelsen U P, Geibel-Zehender A, Boehm N, Olbrich H, Korinthenberg R. et al . Identification of a novel LAMP‐2 mutation responsible for X-chromosomal dominant Danon disease.  Neuropediatrics. 2003;  34 270-273
• 3 Morisawa Y, Fujieda M, Murakami N, Naruse K, Okada T, Morita H. et al . Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome.  J Neurol Sci. 1998;  160 175-179
• 4 Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T. et al . Primary LAMP‐2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).  Nature. 2000;  406 906-910
• 5 Saftig P, Tanaka Y, Lullmann-Rauch R, von Figura K. Disease model: LAMP‐2 enlightens Danon disease (Review).  Trends Mol Med. 2001;  7 37-39
• 6 Sugie K, Yamamoto A, Murayama K, Oh S J, Takahashi M, Mora M. Clinicopathological features of genetically confirmed Danon disease (Review).  Neurology. 2002;  58 1773-1778
• 7 Sugie K, Koori T, Yamamoto A, Ogawa M, Hirano M, Inoue K. Characterization of Danon disease in a male patient and his affected mother.  Neuromuscul Disord. 2003;  13 708-711
• 8 Sarnat H B, Roth S I, Carroll J E, Brown B I, Dungan W T. Lipid storage myopathy in infantile Pompe's disease.  Arch Neurol. 1982;  39 180-183
• 9 Verloes A, Massin M, Lombet J, Grattagliano B, Soyeur D, Rigo J. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency: delineation of a neonatal form.  Am J Med Genet. 1997;  72 135-142
• 10 Yamamoto A, Morisawa Y, Verloes A, Murakami N, Hirano M, Nonaka I. Infantile autophagic vacuolar myopathy is distinct from Danon disease.  Neurology. 2001;  57 903-905